Compare Becton Dickinson and Co (BDX) vs Honest Company Inc (HNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Honest Company Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Honest Company Inc trades at $3.96 (market cap $435.91M). The key difference: Becton Dickinson and Co is far larger — about 95.2× Honest Company Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals.
| BDX | HNST | |
|---|---|---|
Market Cap | $41.51B | $435.91M |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $4.95 |
52-Week Low | $135.49 | $2.10 |
Enterprise Value | $57.97B | $357.31M |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
HNST trades at $3.90, down 2.74% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, while revenue trends show volatility with 2025 revenue at $371.32M. Gross margins improved to 33.89%, but net income remains negative at -$15.69M for 2025. Positive cash flow from operations of $15.12M supports liquidity, though profitability challenges persist.
Outlook is mixed: analyst consensus leans hold (50%) with 30% buy ratings, citing improved fundamentals but limited upside. Key risks include sustained negative net margins and competitive pressures in personal care. The stock's high P/E of 48.83 suggests premium valuation despite lack of profits, requiring careful risk assessment for investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
